FDA Puts New Restrictions on Problematic Birth Control Implant, But Doesn't Take It Off the Market

Some think the restrictions don't go far enough.

Nail, Hand, Manicure, Finger, Nail care, Stomach, Gesture, Abdomen,
(Image credit: Getty Images)

Yesterday U.S. health officials placed new restrictions on a permanent contraceptive implant that is reported to have given thousands of women painful complications—but the metal implant, called Essure, will remain on the market.

The Food and Drug Administration said only women who have had the opportunity to read and sign a brochure about the risks of the device will be able to receive the implant, which is made by Bayer. The checklist of risks must also be signed by the woman's doctor.


Skin, Pink, Hand, Nail, Leg, Lip, Nail care, Foot,

(Image credit: Design by Bridget Burns )

Lingerie, Skin, Leg, Beauty, Thigh, Undergarment, Shoulder, Joint, Human leg, Human body,

(Image credit: Design by Bridget Burns )

The new requirement comes almost two years after the FDA added its strongest warning to Essure, citing problems reported with the nickel-titanium implant. The agency also ordered Bayer to conduct a study of the device's safety.

Patients have reported cases of pain, bleeding, allergic reactions, and cases where the implant punctured the uterus or shifted out of place.

"Despite previous efforts to alert women to the potential complications of Essure, we know that some patients still aren't receiving this important information," said FDA Commissioner Scott Gottlieb, in a statement. "That is simply unacceptable."

An agency spokeswoman said via email that the new requirements "ensure that the device continues to meet our standards for a reasonable assurance of safety and effectiveness."

In a statement after the announcement, Bayer said it will continue to tell health care providers about "the importance of appropriately counseling each patient on the benefits and risks of Essure."

Public health advocates questioned the FDA's new requirement, suggesting patients may not read the lengthy brochure.

"How many people do you know who would carefully read a 22-page document before signing it?" said Diana Zuckerman, president of the National Center for Health Research, a consumer advocacy group. "In addition to being much too long and technical, the information provided will be confusing to many consumers."

Bayer received FDA approval to sell Essure in 2002, and promoted the product to women as the only non-surgical option for permanent birth control. Essure consists of two nickel-titanium coils inserted into the fallopian tubes, where they spur the growth of scar tissue that blocks sperm from fertilizing a woman's eggs.